CSIMarket
 
Prosomnus Inc   (OSA)
Other Ticker:  
 
 
Price: $0.4700 $-0.05 -10.288%
Day's High: $0.6 Week Perf: -16.96 %
Day's Low: $ 0.47 30 Day Perf: -26.56 %
Volume (M): 64 52 Wk High: $ 5.03
Volume (M$): $ 30 52 Wk Avg: $1.33
Open: $0.50 52 Wk Low: $0.35



 Market Capitalization (Millions $) 30
 Shares Outstanding (Millions) 65
 Employees -
 Revenues (TTM) (Millions $) 30
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 1

Prosomnus Inc
Prosomnus Inc is a medical technology company specializing in the design and production of oral devices for the treatment of sleep-related breathing disorders, particularly obstructive sleep apnea (OSA). The company's primary product is the Prosomnus Sleep Technologies, a custom-made oral appliance for OSA patients.

The Prosomnus Sleep Technologies aim to provide a comfortable and effective alternative to traditional continuous positive airway pressure (CPAP) therapy. These devices are designed to maintain an open and unobstructed airway by repositioning and stabilizing the jaw during sleep. They are custom-fit to each patient's unique dental anatomy, ensuring optimal comfort and treatment efficacy.

One of the key advantages of the Prosomnus Sleep Technologies is its compact and non-invasive nature. Unlike CPAP machines, which involve wearing a mask and relying on a constant airflow, the oral appliance is discreet and portable, allowing patients to sleep comfortably and freely move during the night. The devices can also be easily adjusted and fine-tuned to the patient's needs, promoting higher compliance and better treatment outcomes.

Additionally, Prosomnus Inc prioritizes research and innovation. They collaborate with leading sleep specialists and institutions to continually improve their products and contribute to the advancement of sleep-related breathing disorder treatments. The company's commitment to evidence-based practice and clinical outcomes ensures that their devices are safe, effective, and based on the latest scientific knowledge.

Overall, Prosomnus Inc offers a promising solution for individuals suffering from sleep-related breathing disorders. Their custom-made oral devices provide a comfortable and effective treatment option, improving patients' quality of sleep and overall well-being.


   Company Address: 5675 Gibraltar Drive Pleasanton 94588 CA
   Company Phone Number: 537-5337   Stock Exchange / Ticker: NASDAQ OSA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Prosomnus Inc

Prosomnus Inc's Impressive Financial Performance Sets Industry Standard in First Quarter of 2024

Prosomnus Inc, a medical equipment and supplies company, has reported a positive first quarter for 2024, with a decrease in loss per share compared to the previous year. The company's earnings per share improved from -$0.42 to -$0.02, indicating a positive trend in profitability.
Furthermore, Prosomnus Inc witnessed a significant increase in revenue, with a jump of 47.632% to $7.46 million compared to $5.05 million in the same reporting season a year before. However, there was a sequential decline in revenue of -20.199% from $9.35 million.
These positive financial results place Prosomnus Inc ahead of its peers in the Medical Equipment & Supplies sector, as it outperformed the overall sector's 7.27% revenue growth during the same period.

Prosomnus Inc

Prosomnus Inc Announces Revenue Increase to $9.345763 Million for Fiscal Year Ending December 31, 2023

ProSomnus Inc Announces Revenue Increase and Groundbreaking Development
Prosomnus Inc, a leading innovator in the field of sleep medicine, has disclosed a revenue of $9.345763 million for the fiscal span closing December 31, 2023. However, the company reported a net deficit of $-6.869 million for the same reporting season, indicating a decline compared to the previous year's zero gain.
One notable observation is the significant increase in inventories and supplies, reaching $2.0 million. This figure is higher than the preceding quarter and also higher than the corresponding quarter a year ago. This buildup in inventories can suggest positive optimism for future sales and demand for Prosomnus Inc products.
Furthermore, the company saw a notable increase in accounts receivable, which reached a value of $3.8 million compared to the preceding quarter. This rise also signals an increase in demand and is an encouraging sign for investors.

Clinical Study

Revolutionary Remote Patient Monitoring Device by ProSomnus Validates Promising Results for Effective Treatment of Obstructive Sleep Apnea

Published Thu, Feb 22 2024 1:30 PM UTC

In a groundbreaking development, ProSomnus, a leading innovator in the field of sleep medicine, has recently unveiled their next generation remote patient monitoring device for the management of Obstructive Sleep Apnea (OSA). The company's successful pilot study has demonstrated the device's efficacy and potential to revolutionize the treatment landscape for this prevalent s...

Product Service News

ProSomnus: Bridging the Gap to Ensure Uninterrupted Support for Obstructive Sleep Apnea Patients

Published Mon, Jan 29 2024 1:00 PM UTC

In a startling turn of events, Philips Respironics, a leading manufacturer of obstructive sleep apnea (OSA) devices, recently announced the recall and discontinuation of a significant number of its products due to health concerns. As the sleep apnea community reels from this unexpected setback, there is a pressing need for alternative solutions to ensure uninterrupted suppor...

Clinical Study

ProSomnus Precision Oral Appliance Devices Revolutionize Sleep Apnea Treatment, Showcasing Promising Clinical Results and Strong Patient Adherence

Published Tue, Dec 19 2023 1:00 PM UTC



In a recent press release, ProSomnus Inc announced groundbreaking data published by the Cureus Journal of Medical Science that demonstrates the successful treatment of obstructive sleep apnea (OSA) using their precision oral appliance devices. The findings suggest that patients using ProSomnus devices experienced a significant decrease in apnea-hypopnea index (AHI)...






 

Prosomnus Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Prosomnus Inc does not provide revenue guidance.

Earnings Outlook
Prosomnus Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com